User

Welcome, Guest. Please login or register.
April 25, 2024, 12:58:22 pm

Login with username, password and session length


Forums Index

Stats

Members
  • Total Members: 37652
  • Latest: Han2024
Stats
  • Total Posts: 773289
  • Total Topics: 66348
  • Online Today: 690
  • Online Ever: 5484
  • (June 18, 2021, 11:15:29 pm)
Users Online
Users: 2
Guests: 656
Total: 658

Search

Welcome


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.
« previous next »
Pages: [1]   Go Down

Author Topic: FDA Approves Dovato as HIV Switch Option  (Read 5698 times)

0 Members and 1 Guest are viewing this topic.

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 22,388
  • Threads: @jim16309
    • Social Media: Threads
FDA Approves Dovato as HIV Switch Option
« on: August 12, 2020, 12:27:25 am »
 8)

https://www.poz.com/article/fda-approves-dovato-hiv-switch-option

The single-tablet regimen is now approved for previously treated people with an undetectable viral load.

Logged
HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

My Instagram
Threads

Offline Almost2late

  • Member
  • Posts: 1,447
Re: FDA Approves Dovato as HIV Switch Option
« Reply #1 on: October 02, 2021, 05:13:32 pm »
The Dovato combo is holding strong after 3 years.. this is great news.

Quote
Long-Term Data Show Dolutegravir/Lamivudine Non-Inferiority in Efficacy Versus TAF-Based Regimens in HIV

Three-year results from the TANGO study presented at the IDWeek 2021 showed that the 2-drug regimen of dolutegravir/lamivudine (Dovato, GlaxoSmithKline) demonstrated non-inferior efficacy and a high barrier to resistance compared to continuation of tenofovir alafenamide fumarate (TAF)-based regimens of at least 3 drugs in virologically suppressed adults living with HIV-1 who had not experienced prior virologic failure, according to a press release...

https://www.pharmacytimes.com/view/long-term-data-show-dolutegravir-lamivudine-non-inferiority-in-efficacy-versus-taf-based-regimens-in-hiv
Logged
Pages: [1]   Go Up
« previous next »
 

Terms of Membership for these forums
 

© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.